Carmell Therapeutics Stock (NASDAQ:CTCX)
Previous Close
$0.22
52W Range
$0.20 - $4.31
50D Avg
$0.31
200D Avg
$1.27
Market Cap
$4.72M
Avg Vol (3M)
$4.97M
Beta
0.31
Div Yield
-
CTCX Company Profile
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.